Large phase 3 clinical trials demonstrated that the SGLT2 inhibitors dapagliflozin, empagliflozin, and canagliflozin confer protection against fatal and non-fatal CV events and CKD progression over time, when administered in addition to RAAS inhibition, in patients with reduced eGFR (ranging from 20 to 90 mL/min/1.73 m2) and albuminuria (>200–300 mg/g) [12,13,14]. The gene discussed is SLC5A2; the disease is chronic kidney disease.